Assessing AptarGroup (ATR) Valuation After New Nasal Vaccine And Eye Care Technology Developments

Simply Wall St.

Jan 19

AptarGroup (ATR) is back in focus after its LuerVax and Spray Divider nasal devices were selected for CastleVax’s Phase II intranasal COVID-19 vaccine trial, along with renewed attention on its Beat ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2604132876"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2604132876\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2604132876?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/2041000-choice2-main-header/1585186810333","is_english":true,"pubTime":"2026-01-19 21:11","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2604132876","market":"nz","top_or_hot":-1,"title":"Assessing AptarGroup (ATR) Valuation After New Nasal Vaccine And Eye Care Technology Developments","media":"Simply Wall St.","content":"<div>\n<p>AptarGroup (ATR) is back in focus after its LuerVax and Spray Divider nasal devices were selected for CastleVax’s Phase II intranasal COVID-19 vaccine trial, along with renewed attention on its Beat ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/materials/nyse-atr/aptargroup/news/assessing-aptargroup-atr-valuation-after-new-nasal-vaccine-a\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Assessing AptarGroup (ATR) Valuation After New Nasal Vaccine And Eye Care Technology Developments</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAssessing AptarGroup (ATR) Valuation After New Nasal Vaccine And Eye Care Technology Developments\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-01-19 21:11 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/materials/nyse-atr/aptargroup/news/assessing-aptargroup-atr-valuation-after-new-nasal-vaccine-a><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>AptarGroup (ATR) is back in focus after its LuerVax and Spray Divider nasal devices were selected for CastleVax’s Phase II intranasal COVID-19 vaccine trial, along with renewed attention on its Beat ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/materials/nyse-atr/aptargroup/news/assessing-aptargroup-atr-valuation-after-new-nasal-vaccine-a\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ATR","symbol_name":"Aptar","start_time":0,"source_url":"https://simplywall.st/stocks/us/materials/nyse-atr/aptargroup/news/assessing-aptargroup-atr-valuation-after-new-nasal-vaccine-a","article_id":"2604132876","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/2041000-choice2-main-header/1585186810333"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/materials/nyse-atr/aptargroup/news/assessing-aptargroup-atr-valuation-after-new-nasal-vaccine-a","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2604132876","pubTimestamp":1768828270,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"AptarGroup (ATR) is back in focus after its LuerVax and Spray Divider nasal devices were selected for CastleVax’s Phase II intranasal COVID-19 vaccine trial, along with renewed attention on its Beat the Blink eye care platform.\nSee our latest analysis for AptarGroup.\nDespite the fresh attention on its nasal vaccine and eye care platforms, AptarGroup’s share price has been relatively muted, with a 2.73% 1 month share price return and a 1.77% year to date share price return. The 1 year total...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"ATR":"Aptar","ATR.AU":"ASTRON CORP LTD-CDI","BK4126":"金属与玻璃容器","BK7095":"多种金属与采矿"},"translate_title":"在新的鼻疫苗和眼部护理技术开发后评估AptarGroup(ATR)的估值","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ATR":1.5,"ATR.AU":1.5},"content_text":"AptarGroup (ATR) is back in focus after its LuerVax and Spray Divider nasal devices were selected for CastleVax’s Phase II intranasal COVID-19 vaccine trial, along with renewed attention on its Beat the Blink eye care platform. See our latest analysis for AptarGroup. Despite the fresh attention on its nasal vaccine and eye care platforms, AptarGroup’s share price has been relatively muted, with a 2.73% 1 month share price return and a 1.77% year to date share price return. The 1 year total shareholder return of a 19.11% decline points to longer term holders still feeling pressure. If this kind of healthcare product news has your attention, it could be a good moment to scan other opportunities across healthcare stocks and see what else fits your watchlist. So with AptarGroup posting mixed recent returns but trading at a discount to both analyst targets and some intrinsic estimates, should you view ATR as undervalued, or is the market already pricing in its future growth potential? AdvertisementMost Popular Narrative: 21.6% Undervalued The most followed narrative sees AptarGroup’s fair value at roughly US$159 per share versus the last close of US$124.71. This is a sizeable gap and is rooted in detailed long term earnings and margin assumptions. Ongoing investments in innovation, such as next-generation nasal and derma dispensing systems and expansion into active material sciences, are anticipated to capture share in both pharmaceuticals and high-growth dermacosmetic markets. This strengthens AptarGroup's market leadership and supports long-term top-line growth. Read the complete narrative. Curious how steady revenue growth, nudged margins and a richer future P/E are all wired together into that fair value? The full narrative lays out the earnings path, the revenue step up and the profit multiple required to bridge today’s price and that target. Result: Fair Value of $159.14 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, investors still need to weigh ongoing legal costs tied to intellectual property disputes, as well as uncertain demand for emergency medicine and consumer healthcare nasal products, which could pressure margins. Find out about the key risks to this AptarGroup narrative.  Build Your Own AptarGroup Narrative If you see the numbers differently or prefer to test your own assumptions, you can build a custom AptarGroup view in just a few minutes: Do it your way. A good starting point is our analysis highlighting 3 key rewards investors are optimistic about regarding AptarGroup. Looking for more investment ideas? If AptarGroup has sharpened your thinking, do not stop here. Broaden your watchlist with focused stock ideas that match how you like to invest.  Scan for potential value by reviewing these 865 undervalued stocks based on cash flows that align with the kind of pricing gaps you want to track. Spot early trends in automation and data by checking out these 24 AI penny stocks before they sit firmly on everyone else's radar. Hunt for income opportunities through these 12 dividend stocks with yields > 3%, especially if consistent cash payouts matter to your long term plan.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}